Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EMA ‘Extremely Collaborative And Well Prepared’ During Review Of Santhera’s DMD Drug Agamree

16 Oct 2023

• By Eliza Slawther

Cogs — • Source: Shutterstock

Related Content

Santhera Finds ‘Elegant Solution’ For Its Finances With Catalyst DMD Drug Deal

21 Jun 2023

Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna

15 Sep 2023

EMA Backs Approval Of Santhera’s Agamree, Pfizer’s Elrexfio & Several Other New Drugs

13 Oct 2023

EU-UK Trade Deal Allows For Mutual Recognition Of GMP Inspections

30 Dec 2020

Elevidys Clinical Development: Confidence In Surrogate Endpoint A Longstanding Concern For FDA Reviewers

09 Aug 2023

Related Companies

Santhera Pharmaceuticals

PTC Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Additional Topics

Companies Innovation Market Access Pediatrics Rare Diseases Regulation Reimbursement Strategy BioPharmaceutical

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.